ND-1000

**ND-1000** is a Notable Labs-developed, repurposed combination therapy program for pediatric leukemia and adult B-cell blood cancers, including malignancies that relapse after antibody-based therapy or CAR-T-cell treatment. It combines an existing generic anticancer medicine with a natural product; the individual active ingredients were not publicly identified in the available sources. The combination was intended to increase tumor-cell expression of proteins targeted by immuno-oncology therapies, potentially improving susceptibility to CAR-T-cell therapy and related antibody-based approaches. Notable Labs donated pediatric-leukemia commercial rights for pricing, manufacture, and distribution to Cures Within Reach, while retaining adult blood-cancer rights.